PDF herunterladen
Semin intervent Radiol 2024; 41(02): 105-112
DOI: 10.1055/s-0044-1786537
Review Article

Ablation of Primary and Recurrent Thyroid Cancer: Current and Future Perspectives

Toliver Freeman
1   Department of Radiology, Louisiana State Medical School, New Orleans, Louisiana
,
Olivia Pena
2   Division of Interventional Radiology Duke University, Department of Radiology, Durham, North Carolina
,
Alan Alper Sag
3   IR Centers USA, Miami, Florida
,
Shamar Young
4   Division of Interventional Radiology, Department of Medical Imaging, University of Arizona, Tucson, Arizona
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Thyroid cancer is the most common endocrine malignancy, and its incidence is increasing, driven in part by the advent of ultrasound, and subsequent increased detection of small, early thyroid cancers. Yet even for small tumors, thyroidectomy with lymph node dissection remains standard of care. Specific to well-differentiated thyroid cancer, surgery has come under scrutiny as a possible overtreatment, in light of stable and favorable survival rates even as guidelines have allowed fewer radical resections and lymph node dissections over time. Moreover, thyroid cancer unfortunately has a known recurrence rate regardless of therapy, and surgical re-intervention for local structural recurrence is eventually limited by scar. Radioactive iodine therapy, another accepted treatment, is minimally invasive but can only treat patients with iodine-avid tumors. For all of these reasons, image-guided thermal ablation has emerged as a valuable complementary tool as a thyroid-sparing, parathyroid-sparing, voice-sparing, repeatable, minimally invasive outpatient focal therapy for both primary and recurrent well-differentiated thyroid cancers. However, the data are still evolving, and this represents a new patient cohort for some interventional radiologists. Therefore, the goal of this review is to discuss the technique and evidence for ablation of patients with thyroid cancer.

Keywords

interventional radiology - thyroid - cancer - ablation - radiofrequency


Publikationsverlauf

Artikel online veröffentlicht:
10. Juli 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48 (01) 23-35
    CrossrefPubMedGoogle Scholar
  • 2 Chatchomchuan W, Thewjitcharoen Y, Karndumri K. et al. Recurrence factors and characteristic trends of papillary thyroid cancer over three decades. Int J Endocrinol 2021; 2021: 9989757
    CrossrefPubMedGoogle Scholar
  • 3 Chen J, Cao J, Qiu F, Huang P. The efficacy and the safety of ultrasound-guided ablation therapy for treating papillary thyroid microcarcinoma. J Cancer 2019; 10 (21) 5272-5282
    CrossrefPubMedGoogle Scholar
  • 4 Feng J, Jiang Y, Feng Y. Latest evidence of microwave ablation for papillary thyroid microcarcinoma compared with surgery: a systematic review and meta-analysis. Front Oncol 2023; 13: 1088265
    CrossrefPubMedGoogle Scholar
  • 5 Shin JH, Baek JH, Ha EJ, Lee JH. Radiofrequency ablation of thyroid nodules: basic principles and clinical application. Int J Endocrinol 2012; 2012: 919650
    CrossrefPubMedGoogle Scholar
  • 6 Mauri G, Hegedüs L, Bandula S. et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021; 10 (03) 185-197
    CrossrefPubMedGoogle Scholar
  • 7 Ding M, Tang X, Cui D. et al. Clinical outcomes of ultrasound-guided radiofrequency ablation for the treatment of primary papillary thyroid microcarcinoma. Clin Radiol 2019; 74 (09) 712-717
    CrossrefPubMedGoogle Scholar
  • 8 Han ZY, Dou JP, Zheng L. et al. Safety and efficacy of microwave ablation for the treatment of low-risk papillary thyroid microcarcinoma: a prospective multicenter study. Eur Radiol 2023; 33 (11) 7942-7951
    CrossrefPubMedGoogle Scholar
  • 9 Min Y, Wang X, Chen H, Chen J, Xiang K, Yin G. Thermal ablation for papillary thyroid microcarcinoma: how far we have come?. Cancer Manag Res 2020; 12: 13369-13379
    CrossrefPubMedGoogle Scholar
  • 10 Xu B, Zhou NM, Cao WT, Gu SY. Comparative study on operative trauma between microwave ablation and surgical treatment for papillary thyroid microcarcinoma. World J Clin Cases 2018; 6 (15) 936-943
    CrossrefPubMedGoogle Scholar
  • 11 van Dijk SPJ, Coerts HI, Gunput STG. et al. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2022; 148 (04) 317-325
    CrossrefPubMedGoogle Scholar
  • 12 Zhang M, Tufano RP, Russell JO. et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years' follow-up. Thyroid 2020; 30 (03) 408-417
    CrossrefPubMedGoogle Scholar
  • 13 Cavalheiro BG, Shah JP, Randolph GW. et al. Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers (Basel) 2023; 15 (03) 923
    CrossrefPubMedGoogle Scholar
  • 14 Hughes DT, Laird AM, Miller BS, Gauger PG, Doherty GM. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Ann Surg Oncol 2012; 19 (09) 2951-2957
    CrossrefPubMedGoogle Scholar
  • 15 Pacini F, Cetani F, Miccoli P. et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18 (04) 600-604
    CrossrefPubMedGoogle Scholar
  • 16 Young S, Chen T, Golzarian J, Sanghvi T. Ablation of cervical lymph nodes in patients with thyroid cancer: a comparison between cryoablation and percutaneous ethanol injection. J Vasc Interv Radiol 2023; 34 (05) 777-781.e1
    CrossrefPubMedGoogle Scholar
  • 17 Sag AA, Perkins JM, Kazaure HS. et al. Salvage cryoablation for local recurrences of thyroid cancer inseparable from the trachea and neurovascular structures. J Vasc Interv Radiol 2023; 34 (01) 54-62
    CrossrefPubMedGoogle Scholar
  • 18 Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 2013; 25 (01) 14-19
    CrossrefPubMedGoogle Scholar
  • 19 Heilo A, Sigstad E, Fagerlid KH. et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96 (09) 2750-2755
    CrossrefPubMedGoogle Scholar
  • 20 Tofé S, Argüelles I, Álvarez C. et al. Ultrasound-guided ethanol percutaneous ablation versus rescue surgery in patients with locoregional recurrence of papillary thyroid cancer. Clin Exp Otorhinolaryngol 2023; 16 (04) 380-387
    CrossrefPubMedGoogle Scholar
  • 21 Frich PS, Sigstad E, Berstad AE. et al. Long-term efficacy of ethanol ablation as treatment of metastatic lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2022; 107 (05) e2141-e2147
    CrossrefPubMedGoogle Scholar
  • 22 Tofé S, Argüelles I, Serra G, García H, Barcelo A, Pereg V. Ultrasound-guided percutaneous ethanol ablation for the management of recurrent thyroid cancer: evaluation of efficacy and impact on disease course. Int J Thyroid 2020; 13 (02) 128-141
    CrossrefPubMedGoogle Scholar
  • 23 Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E. Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg 2015; 141 (06) 512-518
    CrossrefPubMedGoogle Scholar
  • 24 Suh CH, Baek JH, Choi YJ, Lee JH. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis. Thyroid 2016; 26 (03) 420-428
    CrossrefPubMedGoogle Scholar
  • 25 Guenette JP, Monchik JM, Dupuy DE. Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol 2013; 24 (05) 672-679
    CrossrefPubMedGoogle Scholar
  • 26 Kim HJ, Cho SJ, Baek JH. Comparison of thermal ablation and surgery for low-risk papillary thyroid microcarcinoma: a systematic review and meta-analysis. Korean J Radiol 2021; 22 (10) 1730-1741
    CrossrefPubMedGoogle Scholar
  • 27 Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 2002; 178 (03) 699-704
    CrossrefPubMedGoogle Scholar
  • 28 Paz-Fumagalli R, Li X, Smallridge RC. Ethanol ablation of neck metastases from differentiated thyroid carcinoma. Semin Intervent Radiol 2019; 36 (05) 381-385
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Tufano RP, Pace-Asciak P, Russell JO. et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. The future is now. Front Endocrinol (Lausanne) 2021; 12: 698689
    CrossrefPubMedGoogle Scholar
  • 30 Jensen CB, Pitt SC. Patient perception of receiving a thyroid cancer diagnosis. Curr Opin Endocrinol Diabetes Obes 2021; 28 (05) 533-539
    CrossrefPubMedGoogle Scholar
  • 31 Miyauchi A, Kudo T, Ito Y. et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 2018; 163 (01) 48-52
    CrossrefPubMedGoogle Scholar
  • 32 Hegedüs L, Miyauchi A, Tuttle RM. Nonsurgical thermal ablation of thyroid nodules: not if, but why, when, and how?. Thyroid 2020; 30 (12) 1691-1694
    CrossrefPubMedGoogle Scholar